StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

Veracyte r&d expenses

Research and development expenses are spending on new products and technology.

Veracyte's R&D Expenses for the twelve months ending Jun 30, 2026 was $93.37M, up 31.8% year over year. For fiscal 2025 it was $70.81M, up 2.2% from the year before. Over ten years it grew 18.7% a year on average. The highest annual figure on record is $70.81M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$70.81M+2.2%
FY2024Dec 31, 2024$69.29M+20.9%
FY2023Dec 31, 2023$57.31M+41.1%
FY2022Dec 31, 2022$40.60M+36.1%
FY2021Dec 31, 2021$29.84M+73.5%
FY2020Dec 31, 2020$17.20M+15.8%
FY2019Dec 31, 2019$14.85M+0.2%
FY2018Dec 31, 2018$14.82M+6.8%
FY2017Dec 31, 2017$13.88M-9.4%
FY2016Dec 31, 2016$15.32M+19.8%
FY2015Dec 31, 2015$12.80M+30.5%
FY2014Dec 31, 2014$9.80M+25.5%
FY2013Dec 31, 2013$7.81M+18.2%
FY2012Dec 31, 2012$6.61M-1.1%
FY2011Dec 31, 2011$6.68M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.44M+81.0%
Q1 FY2026Mar 31, 2026$27.10M+52.9%
Q4 FY2025Dec 31, 2025$20.85M+8.1%
Q3 FY2025Sep 30, 2025$15.98M-9.1%
Q2 FY2025Jun 30, 2025$16.26M-1.2%
Q1 FY2025Mar 31, 2025$17.72M+11.0%
Q4 FY2024Dec 31, 2024$19.29M+3.3%
Q3 FY2024Sep 30, 2024$17.57M+31.9%
Q2 FY2024Jun 30, 2024$16.47M+31.3%
Q1 FY2024Mar 31, 2024$15.97M+25.0%
Q4 FY2023Dec 31, 2023$18.67M+65.4%
Q3 FY2023Sep 30, 2023$13.32M+23.7%
Q2 FY2023Jun 30, 2023$12.54M+33.7%
Q1 FY2023Mar 31, 2023$12.77M+39.3%
Q4 FY2022Dec 31, 2022$11.29M+10.1%
Q3 FY2022Sep 30, 2022$10.77M+34.6%
Q2 FY2022Jun 30, 2022$9.38M+50.1%
Q1 FY2022Mar 31, 2022$9.17M+71.8%
Q4 FY2021Dec 31, 2021$10.25M+123.5%
Q3 FY2021Sep 30, 2021$8.01M+98.1%
Q2 FY2021Jun 30, 2021$6.25M+49.9%
Q1 FY2021Mar 31, 2021$5.34M+21.1%
Q4 FY2020Dec 31, 2020$4.59M+3.2%
Q3 FY2020Sep 30, 2020$4.04M+11.0%
Q2 FY2020Jun 30, 2020$4.17M+25.2%
Q1 FY2020Mar 31, 2020$4.41M+28.3%
Q4 FY2019Dec 31, 2019$4.44M+42.2%
Q3 FY2019Sep 30, 2019$3.64M+6.6%
Q2 FY2019Jun 30, 2019$3.33M-27.6%
Q1 FY2019Mar 31, 2019$3.44M-6.5%
Q4 FY2018Dec 31, 2018$3.13M-2.4%
Q3 FY2018Sep 30, 2018$3.42M+12.2%
Q2 FY2018Jun 30, 2018$4.60M+27.7%
Q1 FY2018Mar 31, 2018$3.68M-8.8%
Q4 FY2017Dec 31, 2017$3.20M-10.8%
Q3 FY2017Sep 30, 2017$3.05M-24.0%
Q2 FY2017Jun 30, 2017$3.60M–
Q1 FY2017Mar 31, 2017$4.03M–
Q4 FY2016Dec 31, 2016$3.59M–
Q3 FY2016Sep 30, 2016$4.01M–

More Veracyte figures

See a number that looks wrong?